Sunday, June 21, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 192 of 1,261

  1. US 11666574

    Combination therapy involving diaryl macrocyclic compounds

    TURNING POINT THERAPEUTICS, INC. · Granted Jun 6, 2023 · Expires Jun 1, 2043

    granted

  2. US 11667611

    Compositions and methods for inhibition of the JAK pathway

    Rigel Pharmaceuticals, Inc. · Granted Jun 6, 2023 · Expires Jun 1, 2043

    granted

  3. US 11667643

    RIP1K inhibitors

    Rigel Pharmaceuticals, Inc. · Granted Jun 6, 2023 · Expires Jun 1, 2043

    granted

  4. US 11666671

    Spatial mapping of kidney functions

    Northwestern University · Granted Jun 6, 2023 · Expires Jun 1, 2043

    granted

  5. US 11667683

    Articles comprising a silk polypeptide for antigen delivery

    Ludwig-Maximilians-Universitat Munchen · Granted Jun 6, 2023 · Expires Jun 1, 2043

    granted

  6. US 11660295

    Glucocorticoid receptor modulators to treat cervical cancer

    Corcept Therapeutics Incorporated · Granted May 30, 2023 · Expires May 25, 2043

    granted

  7. US 11660274

    Dosage forms and methods for enantiomerically enriched or pure bupropion

    AXSOME THERAPEUTICS, INC. · Granted May 30, 2023 · Expires May 25, 2043

    granted

  8. US 11660276

    Compositions and methods for treating chronic inflammation and inflammatory diseases

    Infirst Healthcare Limited · Granted May 30, 2023 · Expires May 25, 2043

    granted

  9. US 11661612

    DNA-binding proteins and uses thereof

    Sangamo Therapeutics, Inc. · Granted May 30, 2023 · Expires May 25, 2043

    granted

  10. US 11661617

    Processes for the production of tryptamines

    Compass Pathfinder Limited · Granted May 30, 2023 · Expires May 25, 2043

    granted

  11. US 11661601

    Methods for modulating FMR1 expression

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted May 30, 2023 · Expires May 25, 2043

    granted

  12. US 11661455

    Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety

    Orionis Biosciences, Inc · Granted May 30, 2023 · Expires May 25, 2043

    granted

  13. US 11660352

    Dual function antibodies specific to glycosylated PD-L1 and methods of use thereof

    The Board of Regents of the University of Texas System · Granted May 30, 2023 · Expires May 25, 2043

    granted

  14. US 11660328

    GLP-2 analogs and peptibodies for administration before, during or after surgery

    Takeda Pharmaceutical Company Limited · Granted May 30, 2023 · Expires May 25, 2043

    granted

  15. US 11661441

    Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof

    Apellis Pharmaceuticals, Inc. · Granted May 30, 2023 · Expires May 25, 2043

    granted

  16. US 11661461

    Phospho-Rab antibodies, assays and methods of use thereof

    DENALI THERAPEUTICS INC. · Granted May 30, 2023 · Expires May 25, 2043

    granted

  17. US 11661459

    Artificial cell death polypeptide for chimeric antigen receptor and uses thereof

    Century Therapeutics, Inc. · Granted May 30, 2023 · Expires May 25, 2043

    granted

  18. US 11661593

    Methods of purifying recombinant ADAMTS13 and other proteins and compositions thereof

    Takeda Pharmaceutical Company Limited · Granted May 30, 2023 · Expires May 25, 2043

    granted

  19. US 11661439

    Peptide hydrogels and use thereof

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted May 30, 2023 · Expires May 25, 2043

    granted

  20. US 11661411

    Quinoxaline compounds and uses thereof

    BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA · Granted May 30, 2023 · Expires May 25, 2043

    granted

  21. US 11660571

    Microscale device and method for purification of radiopharmaceuticals

    The Regents of the University of California · Granted May 30, 2023 · Expires May 25, 2043

    granted

  22. US 11661426

    Imidazole-containing inhibitors of ALK2 kinase

    BioCryst Pharmaceuticals, Inc. · Granted May 30, 2023 · Expires May 25, 2043

    granted

  23. US 11661401

    2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitors

    Revolution Medicines, Inc. · Granted May 30, 2023 · Expires May 25, 2043

    granted

  24. US 11660330

    Combination therapy with semaphorin-4D blockade (SEMA4D) and DC1 therapy

    VACCINEX, INC. · Granted May 30, 2023 · Expires May 25, 2043

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.